Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 3, 2014, Pages 483-494

  Said, Rabih ^a,b   Tsimberidou, Apostolia Maria ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute lymphoblastic leukemia; Liposomal vincristine; Pharmacokinetic; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME; PREDNISONE; VINCRISTINE;

CHEMISTRY; DRUG SCREENING; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIPOSOMES; LYMPHOMA, NON-HODGKIN; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84894123836     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.885016     Document Type: Article

References (140)

1. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005;80:1517-27
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
3. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report. Leukemia 2010;24:285-97
4. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-43
5. Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004;104:1624-30
6. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 2011;29:551-65
7. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 2009;27:5175-81
8. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33. Clinical analysis showing the benefit of vincristine-included Brlin-Frankfurt- Munster regimen in ALL.
9. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-61. Phase III Clinical trial showing the benefit of vincristine-included Hyper-CVAD regimen in ALL.
10. Karon MR, Freireich EJ, Frei E. A preliminary report on vincristine sulfate-a new active agent for the treatment of acute leukemia. Pediatrics 1962;30:6
11. Cancer statistics. ACS/Cancer Facts & Figures. American Cancer Society (ACS), Atlanta, Georgia; 2013. Available from: Http://www.cancer.org/ acs/groups/content/@epidemiologysurveilance/documents/document/acspc-037124.pdf [Last accessed 8 January 2014]
12. Selawry OS, Holland JF, Wolman IJ. Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep 1968;52:497-500
13. Evans AE. Vincristine (NSC-67574) in the treatment of children with acute leukemia. Cancer Chemother Rep 1968;52:469-71
14. James DH Jr, George P. Vincristine in children with malignant solid tumors. J Pediatr 1964;64:534-41
15. Whitelaw DM, Cowan DH, Cassidy FR, et al. Clinical experience with vincristine. Cancer Chemother Rep 1963;30:13-20
16. Sullivan MP. Vincristine (NSC-67574) therapy for Wilms' tumor. Cancer Chemother Rep 1968;52:481-4
17. Sutow WW, Berry DH, Haddy TB, et al. Vincristine sulfate therapy in children with metastatic soft tissue sarcoma. Pediatrics 1966;38:465-72
18. Martin J, Compston N. Vincristine sulphate in the treatment of lymphoma and leukaemia. Lancet 1963;2:1080-3
19. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-61
20. Carbone PP, Spurr C, Schneiderman M, et al. Management of patients with malignant lymphoma: A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res 1968;28:811-22
21. Horn Y, Hochman A. The alkaloids of Vinca rosea Linn. in malignant tumors. Oncology 1967;21:214-20
22. Shaw RK, Bruner JA. Clinical evaluation of vincristine (Nsc-67574). Cancer Chemother Rep 1964;42:45-8
23. Carbone PP, Bono V, Frei E III, et al. Clinical studies with vincristine. Blood 1963;21:640-7
24. Goldenberg IS. Vincristine (Nsc-67574) therapy of women with advanced breast cancer. Cancer Chemother Rep 1964;41:7-9
25. Reitemeier RJ, Moertel CG, Blackburn CM. Vincristine (Nsc-67574) therapy of adult patients with solid tumors. Cancer Chemother Rep 1964;34:21-3
26. Gidding CE, Kellie SJ, Kamps WA, et al. Vincristine revisited. Crit Rev Oncol Hematol 1999;29:267-87
27. Kobayashi H, Takemura Y, Holland JF, et al. Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: Mechanism of inoculum effect. Biochem Pharmacol 1998;55:1229-34
28. Jackson DV Jr, Bender RA. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res 1979;39:4346-9
29. Kaspers GJ, Pieters R, Van Zantwijk CH, et al. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 1995;19:407-16
30. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999;44:203-9
31. Lonnerholm G, Frost BM, Abrahamsson J, et al. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol 2008;142:616-21
32. Groninger E, Meeuwsen-de Boer T, Koopmans P, et al. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer 2005;41:98-103
33. Svoboda GH, Johnson IS, Gorman M, et al. Current status of research on the alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don). J Pharm Sci 1962;51:707-20
34. Johnson IS. Historical background of Vinca alkaloid research and areas of future interest. Cancer Chemother Rep 1968;52:455-61
35. Noble RL, Beer CT, Cutts JH. Role of chance observations in chemotherapy: Vinca rosea. Ann NY Acad Sci 1958;76:882-94
36. Svoboda GH. A note on several new alkaloids from Vinca rosea Linn. I. Leurosine, virosine, perivine. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1958;47:834 . First description of antineoplastic effect of vincristine.
37. Johnson IS, Armstrong JG, Gorman M, et al. The vinca alkaloids: A new class of oncolytic agents. Cancer Res 1963;23:1390-427
38. George P, Journey LJ, Goldstein MN. Effect of vincristine on the fine structure of HeLa cells during mitosis. J Natl Cancer Inst 1965;35:355-75
39. Malawista SE, Sato H, Bensch KG. Vinblastine and griseofulvin reversibly disrupt the living mitotic spindle. Science 1968;160:770-2
40. Madoc-Jones H, Mauro F. Interphase action of vinblastine and vincristine: Differences in their lethal action through the mitotic cycle of cultured mammalian cells. J Cell Physiol 1968;72:185-96
41. Stryckmans PA, Lurie PM, Manaster J, et al. Mode of action of chemotherapy in vivo on human acute leukemia-II. Vincristine. Eur J Cancer 1973;9:613-20
42. Himes RH, Kersey RN, Heller-Bettinger I, et al. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 1976;36:3798-802
43. Owellen RJ, Hartke CA, Dickerson RM, et al. Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 1976;36:1499-502
44. Donoso JA, Haskins KM, Himes RH. Effect of microtubule-associated proteins on the interaction of vincristine with microtubules and tubulin. Cancer Res 1979;39:1604-10
45. Mohammad RM, Diwakaran H, Maki A, et al. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 1995;19:667-73
46. Takano Y, Okudaira M, Harmon BV. Apoptosis induced by microtubule disrupting drugs in cultured human lymphoma cells. Inhibitory effects of phorbol ester and zinc sulphate. Pathol Res Pract 1993;189:197-203
47. Geyp M, Ireland CM, Pittman SM. Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line. Leukemia 1996;10:447-55
48. Pittman SM, Strickland D, Ireland CM. Polymerization of tubulin in apoptotic cells is not cell cycle dependent. Exp Cell Res 1994;215:263-72
49. Harmon BV, Takano YS, Winterford CM, et al. Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line. Cell Prolif 1992;25:523-36
50. Baguley BC, Holdaway KM, Thomsen LL, et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 1991;27:482-7
51. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 1991;51:2212-22
52. Pratt CB, Crom DB, Howarth C. The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol 1985;13:330-3
53. Sutow WW, Vietti TJ, Fernbach DJ, et al. Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma. Cancer Chemother Rep 1971;55:67-78
54. Sutow WW. Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms' tumor). Cancer Chemother Rep 1968;52:485-7
55. Karon M, Freireich EJ, Frei E III, et al. The role of vincristine in the treatment of childhood acute leukemia. Clin Pharmacol Ther 1966;7:332-9
56. Krivit W, Chilcote R, Pyesmany A, et al. An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood. Cancer Chemother Pharmacol 1979;2:267-70
57. Weinstein HJ, Mayer RJ, Rosenthal DS, et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983;62:315-19
58. van den Berg H, Stuve W, Behrendt H. Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Med Pediatr Oncol 1997;29:23-7
59. Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006;46:198-202
60. Jackson DV, Case LD, Pope EK, et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol 1985;3:1508-12
61. Holland JF, Scharlau C, Gailani S, et al. Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Res 1973;33:1258-64
62. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
63. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991;9:770-6
64. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-25
65. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-16
66. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low- Grade Lymphoma Study Group. Blood 2005;106:3725-32
67. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
68. Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 1995;13:1080-8
69. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997;8:143-8
70. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 1969;19:367-74
71. Shelanski ML, Wisniewski H. Neurofibrillary degeneration induced by vincristine therapy. Arch Neurol 1969;20:199-206
72. Bradley WG, Lassman LP, Pearce GW, et al. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 1970;10:107-31
73. Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med 1974;80:733-7
74. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986;1:421-7
75. Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 1993;14:61-75
76. Desai ZR, Van den Berg HW, Bridges JM, et al. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982;8:211-14
77. DeAngelis LM, Gnecco C, Taylor L, et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non- Hodgkin's lymphoma. Cancer 1991;67:2241-6
78. Watkins SM, Griffin JP. High incidence of vincristine-induced neuropathy in lymphomas. Br Med J 1978;1:610-12
79. Siegel SE, Moran RG. Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol 1981;3:287-96
80. Evans WE, Petros WP, Relling MV, et al. Clinical pharmacology of cancer chemotherapy in children. Pediatr Clin North Am 1989;36:1199-230
81. Allen JC. The effects of cancer therapy on the nervous system. J Pediatr 1978;93:903-9
82. Cassady JR, Tonnesen GL, Wolfe LC, et al. Augmentation of vincristine neurotoxicity by irradiation of peripheral nerves. Cancer Treat Rep 1980;64:963-5
83. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med 1974;291:127-33
84. Thant M, Hawley RJ, Smith MT, et al. Possible enhancement of vincristine neuropathy by VP-16. Cancer 1982;49:859-64
85. Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;56:361-7
86. Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008;50:769-71
87. Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994;125:642-9
88. Guilhaumou R, Solas C, Bourgarel-Rey V, et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 2011;68:1633-8
89. Bender RA, Castle MC, Margileth DA, et al. The pharmacokinetics of [3H]- vincristine in man. Clin Pharmacol Ther 1977;22:430-5
90. Sethi VS, Burton SS, Jackson DV. A sensitive radioimmunoassay for vincristine and vinblastine. Cancer Chemother Pharmacol 1980;4:183-7
91. Huhtikangas A, Lehtola T, Lapinjoki S, et al. Specific radioimmunoassay for vincristine. Planta Med 1987;53:85-7
92. De Smet M, Van Belle SJ, Storme GA, et al. High-performance liquid chromatographic determination of vincaalkaloids in plasma and urine. J Chromatogr 1985;345:309-21
93. Bloemhof H, Van Dijk KN, De Graaf SS, et al. Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction. J Chromatogr 1991;572:171-9
94. Vendrig DE, Teeuwsen J, Holthuis JJ. Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr 1988;424:83-94
95. Ramirez J, Ogan K, Ratain MJ. Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Cancer Chemother Pharmacol 1997;39:286-90
96. Skolnik JM, Barrett JS, Shi H, et al. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemother Pharmacol 2006;57:458-64
97. Lee JI, Skolnik JM, Barrett JS, et al. A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. J Mass Spectrom 2007;42:761-70
98. Dennison JB, Renbarger JL, Walterhouse DO, et al. Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit 2008;30:357-64
99. Guilhaumou R, Solas C, Rome A, et al. Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:423-7
100. Zhou XJ, Zhou-Pan XR, Gauthier T, et al. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol 1993;45:853-61
101. Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 1993;53:5121-6
102. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006;34:1317-27
103. Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007;321:553-63
104. Castle MC, Mead JA. Investigation of the metabolic fate of tritiated vincristine in the rat by high-pressure liquid chromatography. Biochem Pharmacol 1978;27:37-44
105. Sethi VS, Thimmaiah KN. Structural studies on the degradation products of vincristine dihydrogen sulfate. Cancer Res 1985;45:5386-9
106. Owellen RJ, Root MA, Hains FO. Pharmacokinetics of vindesine and vincristine in humans. Cancer Res 1977;37:2603-7
107. Sethi VS, Jackson DV Jr, White DR, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 1981;41:3551-5
108. Sethi VS, Kimball JC. Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 1981;6:111-15
109. de Graaf SS, Bloemhof H, Vendrig DE, et al. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1995;24:235-40
110. Jackson DV Jr, Sethi VS, Spurr CL, et al. Pharmacokinetics of vincristine infusion. Cancer Treat Rep 1981;65:1043-8
111. Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 1993;17:269-81
112. Groninger E, Meeuwsen-de Boar T, Koopmans P, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 2002;52:113-18
113. Skolnik JM, Zhang AY, Barrett JS, et al. Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. Ther Drug Monit 2010;32:741-8
114. Guilhaumou R, Simon N, Quaranta S, et al. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother Pharmacol 2011;68:1191-8
115. Zhou XJ, Placidi M, Rahmani R. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 1994;14:1017-22
116. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992;44(Suppl 4):1-16; discussion 66-9
117. Lengsfeld AM, Dietrich J, Schultze-Maurer B. Accumulation and release of vinblastine and vincristine by HeLa cells: Light microscopic, cinematographic, and biochemical study. Cancer Res 1982;42:3798-805
118. Ferguson PJ, Cass CE. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: The basis of differential toxicity. Cancer Res 1985;45:5480-8
119. El Dareer SM, White VM, Chen FP, et al. Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys. Cancer Treat Rep 1977;61:1269-77
120. Jackson DV Jr, Sethi VS, Spurr CL, et al. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 1981;41:1466-8
121. Houghton JA, Williams LG, Torrance PM, et al. Determinants of intrinsic sensitivity to vinca alkaloids in xenografts of pediatric rhabdomyosarcomas. Cancer Res 1984;44:582-90
122. Zhigaltsev IV, Maurer N, Akhong QF, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. J Control Release 2005;104:103-11
123. Mayer LD, Bally MB, Loughrey H, et al. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990;50:575-9
124. Webb MS, Harasym TO, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995;72:896-904
125. Johnston MJ, Semple SC, Klimuk SK, et al. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 2006;1758:55-64
126. Johnston MJ, Semple SC, Klimuk SK, et al. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 2007;1768:1121-7
127. O'Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013;31:676-83. Phase II Clinical trial showing the clinical benefit of VSLI in ALL.
128. Krishna R, Webb MS, St Onge G, et al. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 2001;298:1206-12
129. Shan S, Flowers C, Peltz CD, et al. Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. Cancer Chemother Pharmacol 2006;58:245-55
130. Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 2013;71:555-64
131. Bedikian AY, Vardeleon A, Smith T, et al. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol 2006;46:727-37
132. Bedikian AY, Silverman JA, Papadopoulos NE, et al. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol 2011;51:1205-12
133. Maclean A, Symonds G, Ward R. Immunoliposomes as targeted delivery vehicles for cancer therapeutics (Review). Int J Oncol 1997;11:325-32
134. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58:3320-30
135. Nelson RL. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol 1982;10:115-27
136. Van den Berg HW, Desai ZR, Wilson R, et al. The pharmacokinetics of vincristine in man: Reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982;8:215-19
137. Kellie SJ, Koopmans P, Earl J, et al. Increasing the dosage of vincristine: A clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer 2004;100:2637-43
138. Embree L, Gelmon K, Tolcher A, et al. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 1998;41:347-52
139. Yan Z, Zhu ZL, Qian ZZ, et al. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors. Acta Pharmacol Sin 2012;33:852-8
140. Silverman JA, Reynolds L, Deitcher SR. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. J Clin Pharmacol 2013;53(11):1139-45